Skip to main content
Premium Trial:

Request an Annual Quote

'Bioinformatics Is Good for Business'

Speaking at Singularity University earlier this month, Genomera Chief Scientist Raymond McCauley said that the pessimists who say nothing substantive has come of genomics are wrong, and that the data being gathered by researchers will soon drastically change medicine, reports Forbes' Ted Greenwald. The price of a complete genome has been steadily falling, and with the $1,000 genome within reach, many scientists are contemplating what they'll be able to do when the price reaches $1, Greenwald says. McCauley predicts the price will reach $0.01 in a decade, in which case researchers would be able to "sequence everything!" And when that happens, Greenwald says, bioinformatics would be able to "reveal insights that wouldn't otherwise be apparent." He also says that "bioinformatics is good for business," and that "no one doubts that the one-cent genome is coming. Someone will turn it into a billion-dollar business. It's an opportunity waiting to happen."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.